ATE494296T1 - Zusammensetzungen und verfahren für die tumordiagnose und behandlung - Google Patents

Zusammensetzungen und verfahren für die tumordiagnose und behandlung

Info

Publication number
ATE494296T1
ATE494296T1 AT03752035T AT03752035T ATE494296T1 AT E494296 T1 ATE494296 T1 AT E494296T1 AT 03752035 T AT03752035 T AT 03752035T AT 03752035 T AT03752035 T AT 03752035T AT E494296 T1 ATE494296 T1 AT E494296T1
Authority
AT
Austria
Prior art keywords
compositions
treatment
methods
tumor diagnosis
tumor
Prior art date
Application number
AT03752035T
Other languages
English (en)
Inventor
David P Davis
Frederic J Desauvage
William I Wood
Zemin Zhang
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE494296T1 publication Critical patent/ATE494296T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
AT03752035T 2002-09-11 2003-09-05 Zusammensetzungen und verfahren für die tumordiagnose und behandlung ATE494296T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41016602P 2002-09-11 2002-09-11
PCT/US2003/027886 WO2004024063A2 (en) 2002-09-11 2003-09-05 Compositions and methods for the diagnosis and treatment of tumor

Publications (1)

Publication Number Publication Date
ATE494296T1 true ATE494296T1 (de) 2011-01-15

Family

ID=31994078

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03752035T ATE494296T1 (de) 2002-09-11 2003-09-05 Zusammensetzungen und verfahren für die tumordiagnose und behandlung

Country Status (10)

Country Link
US (3) US20120045390A1 (de)
EP (2) EP1578760B1 (de)
JP (4) JP2005537810A (de)
AT (1) ATE494296T1 (de)
AU (3) AU2003268494A1 (de)
CA (2) CA2498004C (de)
DE (1) DE60335636D1 (de)
ES (2) ES2456696T3 (de)
SI (1) SI1546182T1 (de)
WO (2) WO2004024063A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003268494A1 (en) * 2002-09-11 2004-04-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2006034300A2 (en) * 2004-09-17 2006-03-30 Cornell Research Foundation, Inc. Great wall kinases and uses thereof
EP1817328A2 (de) 2004-11-24 2007-08-15 Theraptosis S.A. Neue, als dual-caspase-2/6-inhibitoren nützliche peptide und deren biologische anwendungen
EP2395108A1 (de) * 2004-12-08 2011-12-14 Aventis Pharmaceuticals Inc. Verfahren zur Messung der Resistenz oder Sensitivität gegenüber Docetaxel
JP2008154573A (ja) * 2006-03-31 2008-07-10 Toyobo Co Ltd 可溶性グルコースデヒドロゲナーゼ（ｇｄｈ）を含む組成物の安定性を向上する方法
WO2007134245A2 (en) * 2006-05-12 2007-11-22 Wisconsin Alumni Research Foundation Elastin-like polymer delivery vehicles
SI2056845T1 (en) 2006-08-08 2018-02-28 Rheinische Friedrich-Wilhelms-Universitaet Bonn STRUCTURE AND USE 5 'PHOSPHATE OF OLIGONUCLEOTES
US20090011060A1 (en) * 2007-07-06 2009-01-08 Peter Koepke Campsiandra angustifolia extract and methods of extracting and using such extract
US7879369B2 (en) 2007-09-18 2011-02-01 Selvamedica, Llc Combretum laurifolium Mart. extract and methods of extracting and using such extract
AT506041A1 (de) * 2007-12-10 2009-05-15 Univ Innsbruck Verfahren zur erhöhung der immunreaktivität
US9738680B2 (en) 2008-05-21 2017-08-22 Rheinische Friedrich-Wilhelms-Universität Bonn 5′ triphosphate oligonucleotide with blunt end and uses thereof
EP2343294A1 (de) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituierte Triazolopyridine
EP2508530A1 (de) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Reinigung von triphosphorylierten Oligonucleotiden mit Einfang-Tags
EP2712870A1 (de) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Neuartige RIG-I-Liganden und Herstellungsverfahren dafür
WO2014152831A2 (en) * 2013-03-14 2014-09-25 Health Research, Inc. Targeting peptides and uses thereof
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69635740T2 (de) * 1995-12-18 2006-09-14 Sugen, Inc., South San Francisco Diagnose und behandlung von mit aur-1 und/oder aur-2 assoziierten erkrankungen
US6716575B2 (en) * 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US5885803A (en) * 1997-06-19 1999-03-23 Incyte Pharmaceuticals, Inc. Disease associated protein kinases
WO2002016429A2 (en) * 2000-08-24 2002-02-28 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO1999065928A2 (en) * 1998-06-19 1999-12-23 Genzyme Corporation Polynucleotide population isolated from non-metastatic and metastatic breast tumor tissues
WO2001009316A1 (fr) * 1999-07-29 2001-02-08 Helix Research Institute Nouveaux genes codant la proteine kinase / proteine phosphatase
JP2003514583A (ja) * 1999-11-24 2003-04-22 スージェン・インコーポレーテッド 新規ヒト蛋白質キナーゼおよび蛋白質キナーゼ様酵素
ATE387909T1 (de) * 2000-05-31 2008-03-15 Novartis Vaccines & Diagnostic Verfahren und zusammensetzungen zur behandlung von neoplastischen erkrankungen mittels chemotherapie und strahlungssensibilisatoren
US6974667B2 (en) * 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
MXPA03001643A (es) * 2000-08-24 2004-05-14 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.
WO2002016581A2 (en) * 2000-08-24 2002-02-28 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2002036142A2 (en) * 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
US20040029114A1 (en) * 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
AU2002257004A1 (en) * 2001-02-14 2002-10-15 Protein Design Labs, Inc. Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
AU2002309583A1 (en) * 2001-04-18 2002-11-05 Protein Desing Labs, Inc. Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
WO2002101075A2 (en) * 2001-06-13 2002-12-19 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
CA2451465A1 (en) * 2001-06-18 2002-12-27 Eos Biotechnology Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
AU2002357734A1 (en) * 2001-11-13 2003-05-26 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO2003042661A2 (en) * 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO2003065006A2 (en) * 2002-01-31 2003-08-07 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer
AU2003268494A1 (en) * 2002-09-11 2004-04-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor

Also Published As

Publication number Publication date
EP1578760B1 (de) 2014-02-12
ES2359055T3 (es) 2011-05-18
WO2004024063A2 (en) 2004-03-25
JP2010131015A (ja) 2010-06-17
AU2003270348B2 (en) 2010-08-26
CA2498000C (en) 2015-01-20
AU2003268494A1 (en) 2004-04-30
EP1546182A2 (de) 2005-06-29
JP2006517387A (ja) 2006-07-27
EP1578760A4 (de) 2007-07-11
EP1546182B1 (de) 2011-01-05
EP1578760A2 (de) 2005-09-28
CA2498004A1 (en) 2004-03-25
AU2010201526A1 (en) 2010-05-06
JP2005537810A (ja) 2005-12-15
DE60335636D1 (de) 2011-02-17
US20120045390A1 (en) 2012-02-23
WO2004024064A8 (en) 2005-07-21
CA2498004C (en) 2013-06-11
ES2456696T3 (es) 2014-04-23
WO2004024063A3 (en) 2004-10-14
SI1546182T1 (sl) 2011-04-29
US20040229232A1 (en) 2004-11-18
WO2004024064A2 (en) 2004-03-25
US20130210116A1 (en) 2013-08-15
JP2012046515A (ja) 2012-03-08
CA2498000A1 (en) 2004-03-25
AU2003270348A1 (en) 2004-04-30
EP1546182A4 (de) 2006-09-06

Similar Documents

Publication Publication Date Title
ATE464323T1 (de) Zusammensetzungen und verfahren für die tumor- diagnose und behandlung
DE60238143D1 (de) Zusammensetzungen und verfahren für die diagnose von tumoren
MXPA05005107A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
ATE544748T1 (de) Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen
MXPA03011985A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
ATE494296T1 (de) Zusammensetzungen und verfahren für die tumordiagnose und behandlung
SG155947A1 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2003088808A3 (en) Compositions and methods for the diagnosis and treatment of tumor
ATE396973T1 (de) Benzylether- und benzylamino-beta-sekretase- hemmer zur behandlung von alzheimer-krankheit
DE602006009786D1 (de) Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten
DE602004023721D1 (de) Zusammensetzungen und methoden für die behandlung von herzerkrankungen
MXPA03001643A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
ATE363474T1 (de) Benzimidazole zur behandlung sexueller fehlfunktionen
WO2004096124A3 (en) Compositions and methods for the diagnosis and treatment of tumor
ATE400812T1 (de) Zusammensetzungen und verfahren für verstärkte apoptose
MXPA05008293A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
MXPA03001644A (es) Composiciones y metodos para el diagnostico y tratamiento de tumor.
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen
ATE431348T1 (de) Thiaepothilone zur behandlung von krebserkrankungen
DE60041266D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
ATE476185T1 (de) Verwendung von ciclesonid zur behandlung von entzündlichen darmerkrankungen
DE60320422D1 (de) Verfahren und formulierungen, die sich für die reduktion des cholesteringehalts von eigelb eignen
DE502004008294D1 (de) Neue makrocyclen zur behandlung von krebserkrankungen
WO2003090600A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2003088898A3 (en) Compositions and methods for the diagnosis and treatment of tumor

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1546182

Country of ref document: EP